PT2370096T - Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina - Google Patents

Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina

Info

Publication number
PT2370096T
PT2370096T PT97753040T PT09775304T PT2370096T PT 2370096 T PT2370096 T PT 2370096T PT 97753040 T PT97753040 T PT 97753040T PT 09775304 T PT09775304 T PT 09775304T PT 2370096 T PT2370096 T PT 2370096T
Authority
PT
Portugal
Prior art keywords
antitumal
citarabin
specifically recognize
containing antibodies
combinations containing
Prior art date
Application number
PT97753040T
Other languages
English (en)
Inventor
Lejeune Pascale
Vrignaud Patricia
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40627502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2370096(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PT2370096T publication Critical patent/PT2370096T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
PT97753040T 2008-11-28 2009-11-27 Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina PT2370096T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08291118A EP2191842A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Publications (1)

Publication Number Publication Date
PT2370096T true PT2370096T (pt) 2017-09-08

Family

ID=40627502

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97753040T PT2370096T (pt) 2008-11-28 2009-11-27 Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina

Country Status (40)

Country Link
US (1) US20120093806A1 (pt)
EP (2) EP2191842A1 (pt)
JP (2) JP2012510463A (pt)
KR (1) KR101715958B1 (pt)
CN (2) CN102264386A (pt)
AR (1) AR073425A1 (pt)
AU (1) AU2009321251B2 (pt)
BR (1) BRPI0921858B1 (pt)
CA (1) CA2745005C (pt)
CL (1) CL2011001232A1 (pt)
CO (1) CO6440556A2 (pt)
CR (1) CR20110282A (pt)
DK (1) DK2370096T5 (pt)
EA (1) EA027070B1 (pt)
EC (1) ECSP11011071A (pt)
ES (1) ES2638926T3 (pt)
HN (1) HN2011001423A (pt)
HR (1) HRP20171301T1 (pt)
HU (1) HUE035910T2 (pt)
IL (2) IL213118A (pt)
LT (1) LT2370096T (pt)
MA (1) MA32899B1 (pt)
MX (1) MX344973B (pt)
NI (1) NI201100107A (pt)
NZ (1) NZ593085A (pt)
PA (1) PA8849901A1 (pt)
PE (1) PE20120205A1 (pt)
PL (1) PL2370096T3 (pt)
PT (1) PT2370096T (pt)
PY (1) PY09043372A (pt)
RS (1) RS56248B1 (pt)
SG (1) SG171821A1 (pt)
SI (1) SI2370096T1 (pt)
SM (1) SMT201700403T1 (pt)
TN (1) TN2011000242A1 (pt)
TW (1) TWI436770B (pt)
UA (1) UA104160C2 (pt)
UY (1) UY32266A (pt)
WO (1) WO2010061359A1 (pt)
ZA (1) ZA201104064B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
NZ607473A (en) 2010-09-27 2014-11-28 Morphosys Ag Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2658953T3 (es) 2012-09-25 2018-03-13 Morphosys Ag Combinaciones y usos de los mismos
JP6279065B2 (ja) * 2013-03-13 2018-02-14 サノフイ 抗ｃｄ３８抗体およびカーフィルゾミブを含む組成物
EP3063173B1 (en) * 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PE20170676A1 (es) 2014-09-09 2017-05-22 Janssen Biotech Inc Terapias de combinacion con anticuerpos anti-cd38
EA202092609A1 (ru) 2014-12-04 2021-10-29 Янссен Байотек, Инк. Антитела к cd38 для лечения острого миелолейкоза
CA2986594C (en) 2015-05-20 2025-06-10 Tufts Medical Center, Inc. Anti-CD38 antibodies for the treatment of light chain amyloidosis and other CD38-positive hematological malignancies
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
CN108450004A (zh) * 2015-09-14 2018-08-24 白血病治疗有限责任公司 通过调节RhoH来鉴定新的诊断和治疗
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
HUE053366T2 (hu) 2015-11-03 2021-06-28 Janssen Biotech Inc Szubkután anti-CD38-ellenanyag-készítmények és alkalmazásuk
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CN111565751A (zh) 2017-10-31 2020-08-21 詹森生物科技公司 治疗高危多发性骨髓瘤的方法
US12371506B2 (en) 2018-01-12 2025-07-29 Takeda Pharmaceutical Company Limited Subcutaneous administration of anti-CD38 antibodies
JP7687956B2 (ja) 2019-03-15 2025-06-03 モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 自己抗体介在性自己免疫疾患の処置のための、抗ｃｄ３８抗体及びその医薬組成物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
TW202606756A (zh) 2019-12-05 2026-02-16 美商賽諾菲阿凡提斯美國有限責任公司 用於皮下投予之抗cd38抗體的調配物
CA3204187A1 (en) 2021-01-14 2022-07-21 Stefan Steidl Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
CN113278075B (zh) * 2021-06-18 2021-12-14 芜湖森爱驰生物科技有限公司 一种炎症检测试剂盒
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
JP2003524587A (ja) * 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
AU2007302448C1 (en) * 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2245065A1 (en) * 2008-01-23 2010-11-03 Xencor, Inc. Optimized cd40 antibodies and methods of using the same
EP2191842A1 (en) * 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine

Also Published As

Publication number Publication date
EP2370096A1 (en) 2011-10-05
EA201100868A1 (ru) 2011-10-31
CL2011001232A1 (es) 2012-02-10
EA027070B1 (ru) 2017-06-30
JP2012510463A (ja) 2012-05-10
KR101715958B1 (ko) 2017-03-14
IL213115A0 (en) 2011-07-31
US20120093806A1 (en) 2012-04-19
AU2009321251B2 (en) 2016-06-09
HN2011001423A (es) 2014-01-13
TWI436770B (zh) 2014-05-11
TN2011000242A1 (en) 2012-12-17
UY32266A (es) 2010-06-30
ES2638926T3 (es) 2017-10-24
SMT201700403T1 (it) 2017-11-15
RS56248B1 (sr) 2017-11-30
PA8849901A1 (es) 2010-07-27
MX2011005666A (es) 2011-09-30
SI2370096T1 (sl) 2017-10-30
ZA201104064B (en) 2012-09-26
BRPI0921858B1 (pt) 2022-11-16
UA104160C2 (uk) 2014-01-10
ECSP11011071A (es) 2011-07-29
AR073425A1 (es) 2010-11-03
CR20110282A (es) 2011-09-20
LT2370096T (lt) 2017-09-25
DK2370096T5 (en) 2017-09-18
PE20120205A1 (es) 2012-03-03
BRPI0921858A2 (pt) 2018-10-09
DK2370096T3 (en) 2017-07-17
PL2370096T3 (pl) 2017-10-31
CN107096022A (zh) 2017-08-29
HRP20171301T1 (hr) 2017-10-20
AU2009321251A1 (en) 2010-06-03
PY09043372A (es) 2013-11-01
CA2745005C (en) 2020-08-11
CN102264386A (zh) 2011-11-30
WO2010061359A1 (en) 2010-06-03
IL213118A (en) 2017-08-31
MX344973B (es) 2017-01-12
SG171821A1 (en) 2011-07-28
KR20110096551A (ko) 2011-08-30
EP2191842A1 (en) 2010-06-02
JP2015205893A (ja) 2015-11-19
EP2370096B1 (en) 2017-05-31
TW201023863A (en) 2010-07-01
HUE035910T2 (en) 2018-05-28
NZ593085A (en) 2012-12-21
IL213118A0 (en) 2011-07-31
CO6440556A2 (es) 2012-05-15
CA2745005A1 (en) 2010-06-03
JP6072854B2 (ja) 2017-02-01
IL213115A (en) 2017-08-31
MA32899B1 (fr) 2011-12-01
NI201100107A (es) 2011-09-26

Similar Documents

Publication Publication Date Title
BRPI0922304A2 (pt) combinações antitumorais contendo anticorpos que especificamente reconhecem cd38 e vincristina
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
BRPI0914319A2 (pt) anticorpos estáveis e solúveis que inibem tnfalfa
IL212175B (en) Muc1* antibodies
IL287311A (en) Antibodies and processes for preparing the same
IL213116B (en) Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan
BRPI0912173A2 (pt) anticorpos anti-flt3
BR112013014370A2 (pt) combinações antitumor que contêm anticorpos que reconhecem especificamente cd38 e bortezomib
BRPI0922305A2 (pt) composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0917148A2 (pt) anticorpos anti-cd5
BRPI0908158A2 (pt) Emissor
DK2254806T3 (da) Lukning
BRPI1011005A2 (pt) anticorpos anti-epcam
IL211850A0 (en) Improved antibody molecules
EP2351777A4 (en) ANTI-MUC1 ANTIBODIES
BRPI0909633A2 (pt) anticorpos anti-tyrp1
EP2207803A4 (en) Cd9-specific human antibodies
BRPI0817427A2 (pt) Anticorpo anti-bst2
EP2280264A4 (en) STANDARD AGENTS
DK2103820T3 (da) Fikseringsenhed
BRPI0912769A2 (pt) anticorpos anti-pirb